SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical
MGI Pharma MOGN New patents, anti cancer
An SI Board Since June 1996
Posts SubjectMarks Bans Symbol
1826 45 0 MOGN
Emcee:  Mark Oliver Type:  Unmoderated
Introduction Market Data Compact
Previous 25 | Next 25 | View Recent | Post Message
Go to reply# or date (mm/dd/yy):
ReplyMessage PreviewFromRecsPosted
1376MGI PHARMA 2001 First Quarter Financial Results Conference Call to be Webcast OnDavid Cathcart-4/17/2001
1375MGI PHARMA Initiates Additional Phase 2 Trial of Irofulven In Hormone-RefractoryDavid Cathcart-4/12/2001
1374JIm, Speaking of new personnel, note one of the new nominees for the MGI PharmaDavid Cathcart-4/11/2001
1373The following positions are now available at MGI PHARMA. Regulatory Affairs RegJim Oravetz-4/11/2001
1372MGI Pharma Annual Report media.corporate-ir.netDavid Cathcart-4/9/2001
1371Prostate biz.yahoo.com In one presentation, complete regressions of hormone-refseminole-3/31/2001
1370MGI Pharma Begins New Irofulven Ovarian Cancer Phase 2 Dow Jones Newswires MINNJim Oravetz-3/22/2001
1369MGI PHARMA Launches Hexalen(R) Capsules and Mylocel(TM) Tablets MGI Sales ForceJim Oravetz-3/20/2001
1368MGI PHARMA Secures Equity Financing Facility Mar 1, 2001 MGI PHARMA, INC. todaJim Oravetz-3/1/2001
1367MGI Pharma Results -3: Street Yr Loss View 68c/Shr MOGN Dow Jones Newswires MGI Jim Oravetz-2/14/2001
1366MGI PHARMA Signs Letter Of Intent For Exclusive License To Palonosetron, A PhaseDavid Cathcart-2/13/2001
1365YES biz.yahoo.comseminole-2/7/2001
1364Looks like a good fit.seminole-1/25/2001
1363Barr Names MGI PHARMA, INC. to Market MYLOCEL(TM) Tablets Hydroxyurea Product Lsim1-1/25/2001
1362MGI PHARMA Announces Exclusive License and Distribution Agreement With Barr Labosim1-1/25/2001
1361I'm not sure if this has been posted previously - another in the series of sBiomaven-11/27/2000
1360Looks like there might be some synergy with radiation: <i>Radiat Res 2000Biomaven-11/27/2000
1359Semi OT:Antigenics Inc.(AGEN) expanded a Phase I/II pancreatic cancer trail of iJim Oravetz-11/27/2000
1358Apparently CEO Chuck Blitzer is working on several drug acquisitions. He statedDavid Cathcart-11/15/2000
135710K info:12) Subsequent Events In October 2000, MGI entered into a purchase agrJim Oravetz-11/15/2000
1356<i>Why would MGI base their results in PIII on irofulven vs 5-FU and not gBiomaven-11/14/2000
1355Jim, <<Why would MGI base their results in PIII on irofulven vs 5-FU and David Cathcart-11/14/2000
1354Chemotherapy Systemic chemotherapy uses anticancer drugs that are injected intoJim Oravetz-11/14/2000
1353Jim This data is very exciting when you consider that 29,000 American will be seminole-11/13/2000
1352Jim, nothing particularly exciting in the data. Pancreatic Cancer is the most diVector1-11/12/2000
Previous 25 | Next 25 | View Recent | Post Message
Go to reply# or date (mm/dd/yy):
HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2026 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News